Morgan Stanley analyst Benjamin Swinburne downgrades Paramount Global (NASDAQ:PARA) from Equal-Weight to Underweight and lowers the price target from $32 to $22.
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Oyster Point Pharma (NASDAQ:OYST) with a Buy rating and announces Price Target of $20.